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BRIEF CLINICAL REPORTSTrue primary mediastinal ectopic goiters are very rarely
seen, accounting for fewer than 1% of all goiters.1 They
originate from ectopic thyroid tissue located in the mediasti-
num, without any connection with the cervical thyroid
gland. Here we discuss the case of a patient with a lung
nodule and mediastinal mass with associated bronchial
abnormality.
CLINICAL SUMMARY
Mediastinal enlargement and a solitary pulmonary nodule
were detected on a 68-year-old male patient’s chest radio-
graph during routine annual examination. Computed tomog-
raphy and magnetic resonance imaging revealed a lobulated,
solid, and well-demarcated right paratracheal mass 63 43
4 cm in dimension (Figure 1). The solitary, heterogeneous
parenchymal mass located in the right upper lobe was 4 3
3 3 3 cm in dimension. Results of thyroid function tests
were within reference range. Right tracheal bronchus (bron-
chus suis) was observed on bronchoscopy. Results of bron-
choscopy and bronchial lavage cytologic examination were
not diagnostic. Positron emission tomography (PET)–com-
puted tomography revealed metabolic activity both in the
parenchymal mass (standard uptake values 8.3 early and
9.6 late) and in the nodule of left thyroid lobe (standard up-
take values 4.1 early and 5.1 late; Figure 1). There was no
metabolic activity in the mediastinal mass or mediastinal
lymph node stations. Computed tomographically guided
transthoracic fine-needle aspiration of the parenchymal
mass revealed non–small cell lung carcinoma. Thyroid ultra-
sonography and scintigraphy with sodium pertechnetate Tc
99m showed mixed hypoechoic and hypoactive nodules in
both thyroid lobes. Because of the suspicion of retrosternal
goiter, scintigraphy with iodine 131 was performed,
revealing that the mass took up radioiodine.
The diagnosis was expected to be thyroid malignancy
with lung metastasis. Ultrasonographically guided fine-nee-
dle aspiration biopsy of the nodule in left thyroid gland with
positive results on positron emission tomography was per-
formed for definitive diagnosis. Pathologic examination
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firmed histopathologically in preoperative period. The pre-
sumptive diagnosis at that point was therefore primary
lung carcinoma in early stage and retrosternal goiter. Media-
stinoscopy was not performed.
Through a posterolateral thoracotomy, it was observed
that the tracheal bronchus had connection with only the api-
cal segment of the right upper lobe, and air entry to the re-
maining segments of the right upper lobe came from the
abnormal additional segment bronchus of the middle lobe
bronchus (Figure 2). The parenchymal mass was located
in the apical segment of the right upper lobe. Minor fissure
was absent. Superior bilobectomy and mediastinal lymph
node dissection were performed. An encapsulated mediasti-
nal mass was dissected. The mass had no connection with
the cervical thyroid gland. Histopathologic examiniation re-
vealed poorly differentiated adenocarcinoma (T2N0M0)
and colloidal ectopic thyroid tissue. The patient was dis-
charged from the hospital on postoperative day 7 without
any complications.
DISCUSSION
Ectopic thyroid tissue in thorax without any connection of
cervical thyroid gland is seen very rarely. It is associated
with diagnostic difficulties, potential for malignancy, and
compression of mediastinal structures.2,3 Surgical excision
of ectopic thyroid tissue is recommended for both diagnosis
and treatment.
Ectopic thyroid tissues usually have their vascular supply
from local mediastinal vessels, such as the internal thoracic
and innominate arteries or the intrathoracic aorta, rather than
the cervical blood supply. Surgical incision (sternotomy or
thoracotomy) is determined by the location of the ectopic
thyroid tissue.
Mediastinal thyroid tissue may be PET positive, even it is
benign. This may cause some difficulties in diagnosis. In our
case, the mediastinal mass was PET negative. PET-positive
mediastinal thyroid tissue would be perplexing, necessitat-
ing extra investigations to differentiate it from bulky lymph
nodes and mediastinal tumors. Ectopic goiters do not always
take up radioiodine.
There was a PET-positive thyroid nodule in our patient.
Thyroid incidentaloma is defined as abnormal fluorodeox-
yglucose uptake in the thyroid gland found at PET scan. It
is found at a frequency of 2.3%.4 In the Cohen study, 15
thyroid incidentalomas which were detected in PGT/CT
scans of the patients with known primary malignancies
were sampled and 47% of them were found malignant.4ardiovascular Surgery c Volume 138, Number 1 231
Brief Clinical ReportsWith such a high risk of malignancy, patients with new
thyroid lesions found on PET scan should have a tissue
diagnosis made.
Our patient had some bronchial abnormalities. He had
bronchus suis anomaly, and it had connection with only
the apical segment of the upper lobe. There was no orifice
to the remainder of the upper lobe. There was, however, an
abnormal middle lobe bronchus. Bronchi of the remaining
segments of the upper lobe originated from the middle lobe
bronchus. That was also an unusual abnormality.
In conclusion, ectopic thyroid tissue should be kept in
mind in the differential diagnosis of mediastinal masses.
Ectopic thyroid tissue may be associated with other
tracheobronchial anomalies. If there are additional
FIGURE 1. A, Posteroanterior chest radiography. B, Thoracic computed tomography. C, Thoracic magnetic resonance imaging. D, Positron emission
tomographic image of the patient. White arrows show pulmonary mass in right upper lobe and black arrows show ectopic mediastinal thyroid. Latrogenic
pneumothorx after transthoracic biopsy can be seen in CT section.
FIGURE 2. A, Operative view demonstrating bronchial abnormalities and mediastinal mass. B, Ectopic thyroid tissue.232 The Journal of Thoracic and Cardiovascular Surgery c July 2009
Brief Clinical Reportspathologies, such as lung nodules and lung carcinoma,
there may be some diagnostic and therapeutic difficulties.
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Recent reports1-3 of adverse events related to the use of
aprotinin during complex cardiac surgery and the sudden
suspension of the BART (Blood conservation using antifi-
brinolytics: A randomized trial in a cardiac surgery popula-
tion) trial because of excess mortality in the treatment arm4
highlight the risks of death, acute renal failure, and acute cor-
onary thrombosis during the perioperative period after treat-
ment with this drug. Our concern is that the very real benefits
of the drug in terms of reductions in bleeding, need to return
to the operating room, and rate of transfusion of blood and
blood products2 may be overlooked as a result of the surgical
community’s admirable goal to ‘‘first do no harm.’’ More
specifically, we suspect that there may be a subgroup of
younger patients undergoing complex cardiac surgical pro-
cedures who could derive many of the previously accepted
benefits with a low risk of the recently highlighted adverse
events attributed to the drug.
CLINICAL SUMMARY
Between October 1992 and November 2007, a total of
250 consecutive patients underwent the Ross procedure un-
der the care of a single surgeon (P.D.S.).5 Aprotinin was ad-
ministered routinely to all patients, according to the full
Hammersmith protocol.6 Mean age was 39.5 years (range
15–62 years). Mean total bypass time was 195 minutes,
and mean cumulative crossclamp time was 165 minutes.
Bleeding necessitating return to the operating room oc-
curred in 7 patients (2.8%). Transfusion of blood or blood
products was necessary in 75 patients (30%).
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With regard to adverse events often described as asso-
ciated with the administration of aprotinin, there were no
in-hospital deaths, and acute renal impairment (defined as
a doubling of preoperative creatinine level) occurred in
only 4 patients (1.6%). No patients required hemofiltra-
tion. There were no acute thromboses of any coronary
artery, although 2 patients (0.8%) did require early revi-
sion (1 during the initial time in the operating room and
1 after return to the operating room) as a result of kink-
ing of a coronary artery (this complication was encoun-
tered solely in the early period of the series and has
since been universally prevented by a modification of
technique).
DISCUSSION
It is our impression that young, fit patients undergoing
complex procedures, such as the Ross procedure or adult
congenital cardiac surgery, involving numerous suture lines
and prolonged bypass times can benefit from the use of apro-
tinin. Further, in this select group of patients, who often have
only a small burden of atherosclerotic coronary and renovas-
cular disease, the possible thrombotic complications of apro-
tinin—namely acute coronary occlusion, acute renal failure,
and subsequent in-hospital mortality—may be uncommon.
The well-accepted benefits of reduced blood loss and the
low rates of adverse events in this select group of patients
may therefore tip the balance in favor of the ongoing use
of this drug.
More work is needed. A randomized trial at our institution
addressing whether withholding aprotinin from patients
undergoing the Ross procedure would result in reduced in-
hospital mortality is impossible, however, because our start-
ing death rate is 0%. Similarly, withholding aprotinin in the
hope of discerning a reduction in acute renal failure from our
starting level of 1.6% would require many thousands of
patients.
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